Advertisement

Topics

PubMed Journals Articles About "Zenobia Therapeutics" RSS

07:12 EST 19th February 2018 | BioPortfolio

Zenobia Therapeutics PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Zenobia Therapeutics articles that have been published worldwide.

More Information about "Zenobia Therapeutics" on BioPortfolio

We have published hundreds of Zenobia Therapeutics news stories on BioPortfolio along with dozens of Zenobia Therapeutics Clinical Trials and PubMed Articles about Zenobia Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Zenobia Therapeutics Companies in our database. You can also find out about relevant Zenobia Therapeutics Drugs and Medications on this site too.

Showing "Zenobia Therapeutics" PubMed Articles 1–25 of 1,300+

Epibenthic communities associated with unintentional artificial reefs (modern shipwrecks) under contrasting regimes of nutrients in the Levantine Sea (Cyprus and Lebanon).

Artificial reefs, in the Eastern Mediterranean (Cyprus,) became a popular and frequently used tool, in fisheries and biodiversity conservation management. Even though evaluation studies about the efficacy of artificial reefs are plentiful in the rest of the Mediterranean (Central and Western), in the Eastern Basin they are largely absent. As the Eastern part of the Mediterranean Sea is characterised by unique physical parameters, the necessity to study artificial reefs under these contrasting regimes increa...


Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effective treatment is most needed, but these infections are hard to manage, and progress has been limited. Here, we explore a different approach. Applying an evolutionary perspective to a review of antibiotic prescription studies, we identify infections that likely make a large contribution to resistance evolution ac...

Is the Eye an Extension of the Brain in Central Nervous System Disease?


Introduction to Volume 1 of JOPT Special Issue.

Introduction to Volume 2 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Non-protein biologic therapeutics.

While the therapeutic biologics are dominated by therapeutic proteins, particularly monoclonal antibodies, a wide range of non-protein therapeutic biologics are rapidly gaining ground both in clinical studies and approved products. Many of these first-in-class therapies provide novel treatment modalities and address previously untreatable conditions or undruggable targets. In particular, novel treatments for rare genetic disorders and qualitatively different oncology therapeutics have been approved in the l...

Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099.

Eyes on New Product Development.

Eyes on New Product Development.

Eyes on New Product Development.

Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Oligonucleotide therapeutics have emerged as a third distinct platform for drug discovery within the pharmaceutical industry. Five oligonucleotide-based drugs have been approved by the US FDA and over 100 oligonucleotides drugs are currently at different stages of human trials. Several of these oligonucleotide drugs are modified using the phosphorothioate (PS) backbone modification where one of the nonbridging oxygen atoms of the phosphodiester linkage is replaced with sulfur. In this review, we summarize o...

Correction to: The Effect of Posture on Intraocular Pressure and Systemic Hemodynamic Parameters in Treated and Untreated Patients with Primary Open-Angle Glaucoma, by Katsanos, A., Dastiridou, A.I., Quaranta, L., Rulli, E., Riva, I., Dimasi, V., Tsironi, E.E., and Weinreb, R.N. J Ocul Pharmacol Ther 2017;33(8):598-603. DOI: 10.1089/jop.2017.0030.

The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.

In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics.

Serotonin-2B/2C Receptors Mediate Bovine Ciliary Muscle Contraction: Role in Intraocular Pressure Regulation.

To study the pharmacological profile of the serotonin (5-hydroxytryptamine [5-HT]) receptor subtype mediating contractions in bovine isolated ciliary muscles.

The Current State of Peptide Drug Discovery: Back to the Future?

Over the last decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs, and how this class of compounds can be an excellent complement or even preferable alternative to small molecule and biological therapeutics. In this perspective we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlight...

Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.

Glycyrrhizin (GLY), an inhibitor of high-mobility group box 1 (HMGB1) protects prophylactically against Pseudomonas aeruginosa keratitis. However, the therapeutic potential of GLY to enhance an antibiotic has not been tested and is our purpose.

In Silico Ocular Pharmacokinetic Modeling: Delivery of Topical FK962 to Retina.

To establish the in silico ocular pharmacokinetic modeling for eye drops, and to simulate the dose regimen for FK962 in human choroid/retinal diseases.

Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.

To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT).

Proposed Industry Best Practices in Development and Marketing of Medical Foods for the Management of Chronic Conditions and Diseases while Awaiting Regulation.

Ideal therapeutics have low toxicity and can effectively manage condition(s) or disease(s). The Food & Drug Administration (FDA) marketing category of therapeutics called “medical foods” (MFs) meets such a definition. Medical foods have existed in Federal law since passage the Orphan Drug Act in 1988, which created a category of nutritional therapeutics separate from drugs. Unfortunately, MFs are not widely understood by the medical community or utilized in all patients who need them due to lack of a FD...

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.

Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

The use of lipid formulations has greatly improved the ability to effectively deliver oligonucleotides and has been instrumental in the rapid expansion of therapeutic development programs using oligonucleotide drugs. However, the development of such complex multicomponent therapeutics requires the implementation of unique, scientifically sound approaches to the nonclinical development of these drugs, based upon a hybrid of knowledge and experiences drawn from small molecule, protein, and oligonucleotide the...

Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics.

The nonclinical toxicology program described here was designed to characterize the safety profile of anti-factor D (AFD; FCFD4514S, lampalizumab) to support intravitreal (ITV) administration in patients with geographic atrophy (GA).

Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.

To evaluate the efficacy and tolerance of a new matrix-regenerating agent (RGTA), Cacicol(®), a polymer that mimics heparan sulfates bound to extracellular matrix proteins, avoiding its proteolysis, to treat neurotrophic keratopathy (NK).

Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits.

To investigate the changes in intraocular pressure (IOP), aqueous flow, and outflow facility, as well as efficacy of IOP-lowering drugs before and after sexual development in rabbits.


Advertisement
Quick Search
Advertisement
Advertisement